DNTH

In the past six months, Dianthus Therapeutics' (DNTH) stock price has been impacted by several events. The stock surged significantly, up 89% over six months, due to positive early data from its ongoing late-stage trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), which showed a 75% response rate among the first 40 participants, exceeding the company's 50% target and leading to an 8% stock price jump on a single day in June 2026. The company also delivered positive earnings and revenue surprises for the quarter ended June 2026, reporting a net loss of $50.2 million. In March 2026, Dianthus Therapeutics announced a proposed $400 million underwritten public offering to fund clinical and preclinical development, commercial readiness, and general corporate purposes. Following positive clinical data, investment bank Raymond James reaffirmed a 'Strong Buy' rating with a $125 price target, and Citigroup initiated coverage with a 'Buy' recommendation in September 2026, contributing to a consensus 'Moderate Buy' rating from 15 analysts with an average price target of $129.83. Additionally, there were reports of insider selling in September 2026, with the Chief Accounting Officer and an EVP selling shares totaling over $26 million in the past three months.